Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study
Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-specific oral migraine preventive medication (OMPM) o...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-09-01
|
| Series: | Cephalalgia Reports |
| Online Access: | https://doi.org/10.1177/25158163211040061 |
| _version_ | 1819002922391830528 |
|---|---|
| author | Stewart J Tepper Juanzhi Fang Lujia Zhou Pamela Vo Ahmad Abdrabboh Mrudula Glassberg Matias Ferraris |
| author_facet | Stewart J Tepper Juanzhi Fang Lujia Zhou Pamela Vo Ahmad Abdrabboh Mrudula Glassberg Matias Ferraris |
| author_sort | Stewart J Tepper |
| collection | DOAJ |
| description | Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-specific oral migraine preventive medication (OMPM) on acute medication usage and healthcare resource utilization (HCRU) among migraine patients. Methods: This retrospective US claims analysis included patients (≥18 years) diagnosed with migraine who initiated erenumab (May 01, 2018 and September 30, 2019) or OMPM (May 01, 2016 and October 31, 2017). Cohorts were matched 1:1 using the propensity score (PS) method with stratification. Acute medication usage, HCRU, and a composite endpoint of 1) outpatient visit with a migraine diagnosis and associated acute medication claim, 2) hospital admission with a primary migraine diagnosis, or 3) emergency room visit with a primary migraine diagnosis were assessed 6 months post-treatment initiation. Results: Following PS matching, both cohorts included 2,343 patients. At 6 months, erenumab was associated with significantly less acute medication usage versus OMPM, including number of types of acute medications used, number of claims per person, and proportion of patients using acute medication. HCRU and number of composite events were also significantly lower among erenumab users. Conclusion: Erenumab is more effective than OMPM at reducing acute medication usage and HCRU among migraine patients. Trial registration: N/A. |
| first_indexed | 2024-12-20T23:12:48Z |
| format | Article |
| id | doaj.art-c34ea09e7919453a84bd75c1b089350f |
| institution | Directory Open Access Journal |
| issn | 2515-8163 |
| language | English |
| last_indexed | 2024-12-20T23:12:48Z |
| publishDate | 2021-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cephalalgia Reports |
| spelling | doaj.art-c34ea09e7919453a84bd75c1b089350f2022-12-21T19:23:42ZengSAGE PublishingCephalalgia Reports2515-81632021-09-01410.1177/25158163211040061Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database studyStewart J Tepper0Juanzhi Fang1Lujia Zhou2Pamela Vo3Ahmad Abdrabboh4Mrudula Glassberg5Matias Ferraris6 Geisel School of Medicine at Dartmouth, Hanover, NH, USA RWE and Data Science, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA KMK Consulting Inc., Morristown, NJ, USA HEOR, Novartis Pharma AG, Basel, Switzerland Department of Neuroscience, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA HEOR, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Department of Neuroscience, Novartis Pharma AG, Basel, SwitzerlandBackground: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine. Objective: To compare the real-world effectiveness of erenumab and non-specific oral migraine preventive medication (OMPM) on acute medication usage and healthcare resource utilization (HCRU) among migraine patients. Methods: This retrospective US claims analysis included patients (≥18 years) diagnosed with migraine who initiated erenumab (May 01, 2018 and September 30, 2019) or OMPM (May 01, 2016 and October 31, 2017). Cohorts were matched 1:1 using the propensity score (PS) method with stratification. Acute medication usage, HCRU, and a composite endpoint of 1) outpatient visit with a migraine diagnosis and associated acute medication claim, 2) hospital admission with a primary migraine diagnosis, or 3) emergency room visit with a primary migraine diagnosis were assessed 6 months post-treatment initiation. Results: Following PS matching, both cohorts included 2,343 patients. At 6 months, erenumab was associated with significantly less acute medication usage versus OMPM, including number of types of acute medications used, number of claims per person, and proportion of patients using acute medication. HCRU and number of composite events were also significantly lower among erenumab users. Conclusion: Erenumab is more effective than OMPM at reducing acute medication usage and HCRU among migraine patients. Trial registration: N/A.https://doi.org/10.1177/25158163211040061 |
| spellingShingle | Stewart J Tepper Juanzhi Fang Lujia Zhou Pamela Vo Ahmad Abdrabboh Mrudula Glassberg Matias Ferraris Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study Cephalalgia Reports |
| title | Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study |
| title_full | Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study |
| title_fullStr | Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study |
| title_full_unstemmed | Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study |
| title_short | Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study |
| title_sort | comparative effectiveness of erenumab versus oral preventive medications among migraine patients a us claims database study |
| url | https://doi.org/10.1177/25158163211040061 |
| work_keys_str_mv | AT stewartjtepper comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT juanzhifang comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT lujiazhou comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT pamelavo comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT ahmadabdrabboh comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT mrudulaglassberg comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy AT matiasferraris comparativeeffectivenessoferenumabversusoralpreventivemedicationsamongmigrainepatientsausclaimsdatabasestudy |